206 related articles for article (PubMed ID: 23229224)
21. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
Solaiman KA; Diab MM; Abo-Elenin M
Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study.
Kinge B; Stordahl PB; Forsaa V; Fossen K; Haugstad M; Helgesen OH; Seland J; Stene-Johansen I
Am J Ophthalmol; 2010 Sep; 150(3):310-4. PubMed ID: 20591399
[TBL] [Abstract][Full Text] [Related]
23. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of intravitreal triamcinolone acetonide in long standing diabetic macular edema: a microperimetry and optical coherence tomography study.
Grenga P; Lupo S; Domanico D; Vingolo EM
Retina; 2008 Oct; 28(9):1270-5. PubMed ID: 18664938
[TBL] [Abstract][Full Text] [Related]
25. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions.
Pieramici DJ; Rabena M; Castellarin AA; Nasir M; See R; Norton T; Sanchez A; Risard S; Avery RL
Ophthalmology; 2008 Oct; 115(10):e47-54. PubMed ID: 18708258
[TBL] [Abstract][Full Text] [Related]
26. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.
Risard SM; Pieramici DJ; Rabena MD; Basefsky JC; Avery RL; Castellarin AA; Nasir MA; See RF; Couvillion SS
Retina; 2011 Jun; 31(6):1060-7. PubMed ID: 21283055
[TBL] [Abstract][Full Text] [Related]
27. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.
Heier JS; Campochiaro PA; Yau L; Li Z; Saroj N; Rubio RG; Lai P
Ophthalmology; 2012 Apr; 119(4):802-9. PubMed ID: 22301066
[TBL] [Abstract][Full Text] [Related]
28. [Subjective sensations after intravitreal injection of bevacizumab].
Ach T; Dawczynski J; Königsdörffer E; Augsten R; Strobel J
Klin Monbl Augenheilkd; 2007 Mar; 224(3):180-4. PubMed ID: 17385118
[TBL] [Abstract][Full Text] [Related]
29. Short-term fluctuation of diabetic macular edema after intravitreal ranibizumab injection.
Querques G; Bux AV; Martinelli D; Iaculli C; Del Curatolo MV; Delle Noci N
Retina; 2009 Oct; 29(9):1274-81. PubMed ID: 19696699
[TBL] [Abstract][Full Text] [Related]
30. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema.
Chun DW; Heier JS; Topping TM; Duker JS; Bankert JM
Ophthalmology; 2006 Oct; 113(10):1706-12. PubMed ID: 17011952
[TBL] [Abstract][Full Text] [Related]
31. Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema.
Wang YS; Li X; Wang HY; Zhang ZF; Li MH; Su XN
Chin Med J (Engl); 2011 Feb; 124(3):352-8. PubMed ID: 21362332
[TBL] [Abstract][Full Text] [Related]
32. Diameter of retinal vessels in patients with diabetic macular edema is not altered by intravitreal ranibizumab (lucentis).
Terai N; Haustein M; Siegel A; Stodtmeister R; Pillunat LE; Sandner D
Retina; 2014 Jul; 34(7):1466-72. PubMed ID: 24457978
[TBL] [Abstract][Full Text] [Related]
33. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema.
Ozkiriş A
Eye (Lond); 2009 Mar; 23(3):616-20. PubMed ID: 18437176
[TBL] [Abstract][Full Text] [Related]
34. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
Spaide RF; Chang LK; Klancnik JM; Yannuzzi LA; Sorenson J; Slakter JS; Freund KB; Klein R
Am J Ophthalmol; 2009 Feb; 147(2):298-306. PubMed ID: 18929354
[TBL] [Abstract][Full Text] [Related]
35. [Combined pharmacosurgery as treatment for diabetic macular edema: core pars plana vitrectomy and intravitreal injection of bevacizumab and triamcinolone].
Naser H; Koss MJ; Singh P; Koch F
Klin Monbl Augenheilkd; 2011 Oct; 228(10):910-4. PubMed ID: 21997827
[TBL] [Abstract][Full Text] [Related]
36. [Evaluation of possible prognostic factors for the course of visual acuity after intravitreal ttriamconolone acetonide].
Schmidt B; Krummenauer F; Lösche CC
Klin Monbl Augenheilkd; 2012 Jan; 229(1):56-61. PubMed ID: 21837585
[TBL] [Abstract][Full Text] [Related]
37. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months.
Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
Retina; 2009; 29(10):1396-403. PubMed ID: 19898177
[TBL] [Abstract][Full Text] [Related]
38. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Brown DM; Chen E; Mariani A; Major JC;
Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
[TBL] [Abstract][Full Text] [Related]
39. The area of fixation covaries with short-term changes in visual acuity after anti-vascular endothelial growth factor treatment in patients with diabetic macular oedema.
Jakobsen NS; Larsen DA; Bek T
Acta Ophthalmol; 2018 Nov; 96(7):744-748. PubMed ID: 29687595
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial.
Lam DS; Lai TY; Lee VY; Chan CK; Liu DT; Mohamed S; Li CL
Retina; 2009 Mar; 29(3):292-9. PubMed ID: 19287286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
